CA
NZ
UK
AU
IND
US
…
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Fennec Pharmaceuticals develops and commercializes therapies to reduce chemotherapy‑induced hearing loss in pediatric patients; its lead sodium thiosulfate product targets cisplatin ototoxicity. Long‑term growth may be driven by wider clinical adoption, regulatory and geographic expansion and potential label extensions, which could make it attractive to investors seeking exposure to a niche pediatric supportive‑care franchise.
Material risks include dependence on a single product, limited commercial history, reimbursement and pricing pressures, regulatory or clinical setbacks and the potential need for additional funding that could dilute shareholders.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -10.27M | -0.07M | -16.05M | -23.71M | -17.35M |
| Net income | -10.27M | -0.44M | -16.05M | -23.86M | -17.36M |
| Selling general administrative | 46.91M | 23.05M | 20.59M | 17.72M | 12.24M |
| Selling and marketing expenses | - | 18.43M | 12.12M | 2.79M | - |
| Gross profit | 41.59M | 44.35M | 19.99M | 1.45M | - |
| Reconciled depreciation | 0.10M | 0.80M | 0.29M | - | 0.02M |
| Ebit | - | 4.00M | -12.94M | -22.59M | -17.22M |
| Ebitda | -6.86M | 4.80M | -12.65M | -22.54M | -17.18M |
| Depreciation and amortization | - | 0.80M | 0.29M | 0.05M | 0.04M |
| Operating income | -6.86M | 2.57M | -12.77M | -22.59M | -17.22M |
| Other operating expenses | 52.29M | 44.97M | 34.02M | 24.12M | 17.22M |
| Interest expense | 2.18M | 4.07M | 3.39M | 0.98M | 0.13M |
| Tax provision | 0.11M | 0.36M | 0.00M | - | - |
| Interest income | 0.79M | 2.64M | 0.44M | 0.20M | 0.12M |
| Net interest income | -1.29M | -2.48M | -2.95M | -0.93M | -0.07M |
| Income tax expense | - | 0.36M | 3.39M | 0.15M | 0.02M |
| Total revenue | 45.42M | 47.54M | 21.25M | 1.53M | 0.00M |
| Total operating expenses | 48.46M | 41.79M | 32.76M | 24.04M | 17.22M |
| Cost of revenue | 3.83M | 3.18M | 1.26M | 0.09M | - |
| Total other income expense net | -3.41M | -2.64M | -3.27M | -1.12M | -0.12M |
| Net income from continuing ops | -9.74M | -0.44M | -16.05M | -23.71M | -17.35M |
| Net income applicable to common shares | - | -0.44M | -16.05M | -23.71M | -17.35M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 70.07M | 44.95M | 26.86M | 26.94M | 22.41M |
| Other current assets | 5.10M | 0.47M | 0.04M | 0.06M | 0.25M |
| Total liab | 35.02M | 50.82M | 38.49M | 29.51M | 6.64M |
| Total stockholder equity | 35.05M | -5.87M | -11.62M | -2.57M | 15.77M |
| Deferred long term liab | - | - | - | 0.21M | 0.03M |
| Other current liab | 5.62M | - | 3.75M | 2.22M | 0.88M |
| Common stock | 189.56M | - | 144.31M | 142.59M | 140.80M |
| Capital stock | 189.91M | 145.61M | 144.31M | 142.59M | 140.80M |
| Retained earnings | -229.36M | -219.68M | -219.25M | -203.20M | -179.49M |
| Other liab | - | - | - | 0.26M | 4.99M |
| Other assets | - | - | - | 0.21M | 0.03M |
| Cash | 36.72M | 26.63M | 13.27M | 23.77M | 21.10M |
| Cash and equivalents | - | - | - | 23.77M | 21.10M |
| Total current liabilities | 10.50M | 6.92M | 7.55M | 4.61M | 1.65M |
| Current deferred revenue | 0.25M | - | - | - | - |
| Net debt | -36.72M | - | 17.68M | 1.12M | -16.11M |
| Short term debt | - | - | 0.02M | 0.00M | 0.00M |
| Short long term debt total | - | - | 30.95M | 24.90M | 4.99M |
| Other stockholder equity | 73.61M | - | 62.07M | 56.80M | 53.21M |
| Total current assets | 66.56M | 44.12M | 26.86M | 26.73M | 22.39M |
| Net tangible assets | - | - | - | -2.57M | 15.77M |
| Net receivables | 23.18M | 12.88M | 8.81M | 1.54M | - |
| Long term debt | - | 19.34M | 30.93M | 24.90M | 5.00M |
| Inventory | 1.56M | 1.06M | 2.16M | 0.58M | - |
| Accounts payable | 4.63M | 3.24M | 3.78M | 2.39M | 0.78M |
| Accumulated other comprehensive income | 1.24M | - | 1.24M | 1.24M | 1.24M |
| Non currrent assets other | 3.50M | 0.82M | 0.01M | - | 0.03M |
| Non current assets total | 3.50M | 0.82M | 0.01M | 0.21M | 0.03M |
| Capital lease obligations | 0.00M | 0.00M | 0.02M | - | - |
| Long term debt total | - | - | - | 25.00M | 5.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Change to liabilities | - | - | - | 1.61M | -0.79M |
| Net borrowings | -19.48M | -13.00M | 5.00M | 20.17M | 4.99M |
| Total cash from financing activities | 25.01M | -13.62M | 6.64M | 20.73M | 4.98M |
| Change to operating activities | - | - | - | 1.61M | -0.14M |
| Net income | -9.91M | -0.44M | -16.05M | -23.71M | -17.35M |
| Change in cash | 8.83M | 13.37M | -10.51M | 2.67M | -9.24M |
| Begin period cash flow | 27.89M | 13.27M | 23.77M | 21.10M | 30.34M |
| End period cash flow | 36.72M | 26.63M | 13.27M | 23.77M | 21.10M |
| Total cash from operating activities | -14.67M | 26.98M | -17.14M | -18.06M | -14.22M |
| Issuance of capital stock | 42.05M | - | - | - | 0.00M |
| Depreciation | 0.10M | 0.80M | 0.00M | - | 0.02M |
| Change to inventory | -1.30M | 0.58M | -1.58M | -0.58M | -0.58M |
| Change to account receivables | -12.66M | -7.87M | -7.27M | -1.54M | -1.54M |
| Sale purchase of stock | - | -0.18M | -0.08M | 0.93M | 0.03M |
| Other cashflows from financing activities | -0.19M | -0.44M | 1.64M | 25.73M | 4.98M |
| Change to netincome | - | - | - | 4.40M | 4.04M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -15.09M | 16.94M | -6.78M | 1.10M | -0.93M |
| Stock based compensation | 7.03M | 5.06M | 5.35M | 4.09M | 3.75M |
| Other non cash items | 10.33M | 4.61M | 0.33M | 0.47M | 0.31M |
| Free cash flow | -14.67M | 26.98M | -17.14M | -18.06M | -14.22M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FRX Fennec Pharmaceuticals Inc |
0.20 1.35% |
14.99 | - | 21.01 | 6.95 | 6.35 | 4.25 | 20.27 |
| EPRX Eupraxia Pharmaceuticals Inc |
-0.17 1.76% |
9.48 | - | - | - | 8.45 | - | -3.88 |
| MSCL Satellos Bioscience Inc. |
- -% |
9.00 | - | - | - | 5.85 | - | 6.47 |
| HBP Helix BioPharma Corp. |
-0.10 9.80% |
0.92 | - | 3.87 | 4263.36 | 9.74 | 4422.35 | -6.36 |
| SVA Sernova Corp |
-0.01 4.35% |
0.11 | - | - | 65.86 | 24.15 | 36.69 | -11.27 |
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709
919 636 4530
35
| Name | Title | Year Born |
|---|---|---|
| Mr. Rostislav Raykov | CEO & Director | 1976 |
| Mr. Robert C. Andrade | Chief Financial Officer | 1975 |
| Mr. Mark Meier | Sr. VP of Commercial | NA |
| Mr. Mark Gowland | Controller | NA |
| Mr. Lei Fang | Pres of Pharstat Inc | NA |
| Ms. Anne McKay | Regulatory Consultant | 1954 |
| Mr. Alexander D. Smith M.S. | Consultant | NA |
| Mr. Terry Evans | Chief Commercial Officer | NA |
| Dr. Pierre S. Sayad M.S., Ph.D. | Chief Medical Officer | NA |
| Ms. Christiana Cioffi M.B.A. | Chief Strategy Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+2.10%
Communication Services
+1.48%
Consumer Cyclical
+2.12%
Consumer Defensive
+1.59%
Energy
-2.52%
Financial Services
+1.11%
Financials
-6.05%
Healthcare
+2.12%
Industrials
-0.12%
Real Estate
+1.25%
Technology
-0.07%
Utilities
+0.57%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...